A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years ...
GenSight Biologics announces efficacy and safety results for Lumevoq gene therapy at the conclusion of the REFLECT phase III clinical study: Paris Thursday, February 13, 2025, 17: ...
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback